Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
Rezolute highlighted data presentations at the Endocrine Society meeting, reviewing previously reported results from the Phase 3 sunRIZE study of ersodetug in congenital hyperinsulinism. An Expanded Access Program case series showed that 75% of tumor HI patients achieved complete discontinuation of IV dextrose/TPN.
Key figures
- Drug Name
- ersodetug
- Phase Of Trial
- Phase 3
- Eap patients
- 9
- Eap discontinuation rate
- 75%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.